Blood Cancer News and Research

RSS

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026

New insights into predicting myeloma drug response

Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited tools at their disposal to predict who is most likely to benefit or suffer from a particular myeloma therapy.

28 Apr 2026

Repurposed drugs may provide safer treatments for aggressive childhood leukemia

Three clinically available drugs could pave the way for safer and more effective treatments for one of the most aggressive forms of childhood leukaemia, a new study suggests.

27 Apr 2026

New strategy boosts natural killer cells to fight cancer

Scientists have developed a strategy to boost the cancer-fighting power of natural killer (NK) cells, part of the immune system's first line of defense.

24 Apr 2026

Study reframes Hodgkin lymphoma as a cancer of failed cell development

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis."

24 Apr 2026

Study maps the evolution of myeloid leukemia in children with Down syndrome

It may be possible to identify which pre-cancerous cells will develop into a rare type of blood cancer, due to new research showing that a single genetic change drives myeloid leukemia in children with Down syndrome.

23 Apr 2026

Chronic wildfire smoke exposure may raise long-term cancer risks

Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder, and blood cancer, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

21 Apr 2026

Researchers identify molecular link between autoimmune disease and lymphoma risk

Patients with autoimmune diseases such as lupus and rheumatoid arthritis have an increased risk of developing lymphoma, a form of blood cancer that affects the lymphatic system.

13 Apr 2026

OICR funds four Ontario teams to develop next-generation cancer therapies

Better cancer care depends on better treatment options. That's why the Ontario Institute for Cancer Research (OICR) is supporting four Ontario-based research teams working to develop the next generation of cancer therapies that are designed to be more effective at destroying tumors, have reduced side effects, and make cancer less likely to return.

9 Apr 2026

Study finds increasing rates of therapy-related acute myeloid leukemia

Some therapies used to treat cancer may increase the risk of later developing cancers that affect the blood.

6 Apr 2026

Researchers identify markers of lymphoma recurrence

Follicular Lymphoma (FL) is a type of blood cancer and a form of non-Hodgkin's lymphoma. Thanks to new treatment breakthroughs, about 80% of FL patients have a survival rate of more than 10 years.

31 Mar 2026

Early blood test could guide personalized lymphoma treatment decisions

Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of treatment: an antibody designed to wipe out cancerous B cells plus a combination of four chemotherapy drugs.

25 Mar 2026

Implantable device boosts immune cells to fight cancer effectively

Immunotherapy has transformed cancer treatment by harnessing the body's own immune system to fight disease.

17 Mar 2026

New method creates longer lasting CAR T cells for cancer therapy

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into patients to fight cancer and HIV, addressing a major limitation of current treatments.

13 Mar 2026

Rapid Novor receives Ontario Ministry of Health provisional license for EasyM® blood-based MRD test for multiple myeloma

Rapid Novor Inc., a Canadian biotechnology leader, announced today that its diagnostic laboratory has received a provisional license from the Ontario Ministry of Health (MOH) for its EasyM® assay, enabling the company to begin testing patients in Canada.

From Rapid Novor Inc 11 Mar 2026

Common cardio drugs proven safe in myeloma patients

Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international research.

1 Mar 2026

HIT cell therapy eradicates solid tumors in preclinical models

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers.

26 Feb 2026

Researchers find new way to halt leukemia stem cell growth

In a new study published in Nature Communications, a research team at the University of Oslo have examined how cancer cells develop in the bone marrow and whether it might be possible to stop them.

18 Feb 2026

Optimization of CAR T cells to destroy solid tumors

A team led by LMU physician Sebastian Kobold has found a way to allow the body's immune system to destroy solid tumors.

16 Feb 2026

Case report examines potential cancer risks after mRNA vaccination

A new case report was published in Volume 17 of Oncotarget on February 6, 2026, titled "Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms."

12 Feb 2026